Drug Discovery Featured Articles & Applications

  1. Developing Oral Dosage Forms: An Approach For Faster Path To Market
    12/11/2017

    How an agnostic and data-driven approach early on can optimize the development pathway to bring the molecule to the market faster.

  2. Advances In Immunotherapy For Cancer
    11/29/2017

    Over the past decade, advances in oncology research have resulted in many new treatment options that include immunotherapies. This article examines these newer therapies in more detail.

  3. Multiplexing: Managing Risk With Proven, Single-Use Solutions
    11/27/2017

    With many uncertainties when introducing a new drug to market, seeking manufacturing flexibility to accommodate diverse demands and production needs is key.

  4. The Unique Needs Of The HPAPI Market: Are You Prepared?
    11/22/2017

    To take advantage of the growing HPAPI market, a company must have the proper controls in place to safely handle these potent compounds and successfully bring its drug to market.

  5. Are You Prepared For The Complexity Of Pediatric Drug Development?
    11/22/2017

    Pediatric drug development requires a formulation designed to fit the specific needs of that patient population. Not considering these requirements early enough could add significant delays.

  6. Understanding Biomarkers For Better Drug Discovery And Development
    11/2/2017

    In collaboration with Amplion Inc., we investigated biomarker usage within 24 companies focused on immunotherapy. This article shares exciting insights from our analysis, including which biomarkers are the most popular and how those biomarkers are being utilized by each company.

  7. Let The Molecule Decide
    11/2/2017

    Formulation techniques and technologies can easily become more habit than science, but a single technology does not work for all compounds. Each new drug is unique and deserves a fresh approach to formulation.

  8. The Race to Phase III: A Cautionary Tale of Scalability
    10/30/2017

    Follow the paths of two companies as they learn how a science-led, risk-based development approach yields a more successful outcome in the long run.

  9. Achieving Optimal mAb Titer and Quality Through Cell Culture Media and Supplement Optimization
    10/25/2017

    In addition to having the optimal cell line and process, it is crucial to have the optimal cell culture medium and feed to maximize  performance potential.

  10. Optimizing Titer and Use of a Specific Enzyme for Generating a Fully Processed Antibody
    10/25/2017

    An outline of the cell development and process scale-up for an antibody program in which the antibody requires additional processing by a site-specific enzyme for correct functionality.